Histide

Switzerland
Schindellegi, Schwyz, Switzerland, 8834

Company profile

Histide company profile

Histide is a biotech intellectual property platform company pioneering a new class of non-mutagenic extracellular therapeutic agents called Cell Recoding Molecules™ (CRMs). This innovative platform builds on Histide’s expertise in the mechanisms underlying the cell’s microenvironmental sensing and signal transduction processes. The CRMs promote and stimulate the cell’s natural capacities to redirect its own fate by integrating accurate extracellular signals. This is at the heart of Histide’s groundbreaking approach of addressing diseases called Recoding Therapeutics™, that goes beyond traditional cell, gene or RNA based therapies. Histide has a technological breakthrough with vast indication spectra of pharmaceuticals, medical devices and medical cosmetics. Their mission : Establish Cell Recoding Molecules (CRMs) as new class of therapeutic solutions. Their vision : To unlock the potential of Recoding Therapeutics by establishing an ecosystem of teams and partners, all committed to providing enhanced therapeutic solutions across diverse areas and routes of administration, for diseases that are untreatable or undruggable today.

Business identity

Contact email
[email protected]
Phone number
+41 43 888 2577
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0+
Founded
2014-01-01, Year

Headquarters

Postal code
8834
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
1
Total equity funding
$4.7M
Last funding
Series A / $4.7M / 2014-11-10
Last equity funding
Series A / $4.7M
Investors
2
Lead investors
1
Founders
2
Articles
5

Founders and investors

Founders

Omar ZouaniRomain Julia

Lead investors

Partner Capital

Investors

Open Field CapitalPartner Capital